Format

Send to

Choose Destination
Hum Vaccin Immunother. 2018 Nov 27. doi: 10.1080/21645515.2018.1553594. [Epub ahead of print]

Epidemiologic challenges in norovirus vaccine development.

Author information

1
a Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.
2
b Epidemic Intelligence Service, CDC.

Abstract

Norovirus is the leading cause of acute gastroenteritis (AGE) worldwide. In the United States norovirus is estimated to cause 19-21 million illnesses, 1.7-1.9 million outpatient visits, 56,000-71,000 hospitalizations, and 570-800 deaths annually. Through direct costs and loss of productivity, norovirus disease cost the US economy more than $5.5 billion annually. Due to the lack of available therapies to treat norovirus infections and their highly infectious nature, preventing norovirus illness through vaccination is an appealing strategy. Currently, several norovirus vaccines are in development, including five vaccines in preclinical trials, an oral monovalent vaccine (Vaxart, Inc.) that recently completed a phase IB clinical trial, and a bivalent intramuscular vaccine (Takeda Pharmaceutical Company Limited) in a phase IIB clinical trial. However, no norovirus vaccines are currently available on the market. In this commentary we aim to describe some of the barriers faced in norovirus vaccine development, particularly focusing on vaccine effectiveness and defining the target population.

KEYWORDS:

Norovirus; effectiveness; efficacy; epidemiology; vaccine development

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center